Skye Bioscience, Inc. Common Stock Asset Resilience Ratio
Skye Bioscience, Inc. Common Stock asset resilience ratio. Skye Bioscience, Inc. Common Stock (SKYE) has an Asset Resilience Ratio of 18.09% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Skye Bioscience, Inc. Common Stock fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Skye Bioscience, Inc. Common Stock (2015–2025)
Asset resilience ratio of Skye Bioscience, Inc. Common Stock from 2015 to 2025. This chart shows how Skye Bioscience, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read Skye Bioscience, Inc. Common Stock total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Skye Bioscience, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Skye Bioscience, Inc. Common Stock.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.00 Million | 18.09% |
| Total Liquid Assets | $2.00 Million | 18.09% |
Asset Resilience Insights
- Good Liquidity Position: Skye Bioscience, Inc. Common Stock maintains a healthy 18.09% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Skye Bioscience, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Skye Bioscience, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Skye Bioscience, Inc. Common Stock Asset Resilience Ratio by Year (2015–2025)
Skye Bioscience, Inc. Common Stock asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for Skye Bioscience, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 70.12% | $19.85 Million | $28.31 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $72.76 Million | -- |
| 2023-12-31 | -76.05% | $-9.08 Million | $11.94 Million | -77.11pp |
| 2015-12-31 | 1.07% | $37.50K | $3.51 Million | -- |
About Skye Bioscience, Inc. Common Stock
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1… Read more